Literature DB >> 23679330

Inhibition of proliferation of cervical and leukemic cancer cells by penicillin G.

Aditya Banerjee1, Meetu Dahiya, M T Anand, Sudhir Kumar.   

Abstract

Cancer, despite all the efforts, still causes one in five deaths worldwide. Surgery, chemotherapy and radiotherapy provide inadequate protection and instead affect normal cells along with cancer cells. The search for cancer cures from natural products (plants and animals) has been practice for over a decade and the use of purified chemical to treat cancer still continues. Several studies have been undertaken during last three decades to find the anti-cancerous property of various plant extract and toxins secreted by animals and micro-organism. These lead to the discovery of several promising molecule having anticancer activity, some of which are in clinical trial and may emerged to be a potential future drug in cancer therapy. In this study we have used penicillin to evaluate its anti-cancer activity. It shown significant effects at cellular and molecular levels against growth of HeLa and K562 cell lines.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23679330     DOI: 10.7314/apjcp.2013.14.3.2127

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  2 in total

1.  In vitro mechanistic studies on α-amanitin and its putative antidotes.

Authors:  Daniela Ferreira Rodrigues; Ricardo Pires das Neves; Alexandra T P Carvalho; Maria Lourdes Bastos; Vera M Costa; Félix Carvalho
Journal:  Arch Toxicol       Date:  2020-03-19       Impact factor: 5.153

2.  Antitumor activity of new chemical compounds in triple negative mammary adenocarcinoma models.

Authors:  María V Giolito; Cristian M Camacho; Maitena Martinez-Amezaga; Carla I Traficante; Rocío A Giordano; Patricia G Cornier; Ernesto G Mata; Carina Ml Delpiccolo; Dora B Boggián; Antonela Del Giúdice; Leandro E Mainetti; Olga G Scharovsky; Viviana R Rozados; María J Rico
Journal:  Future Sci OA       Date:  2020-01-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.